They can block specific effector cells in SLE [5], the generation of regulatory T cell subset, and release various anti-inflammatory cytokines, including interleukin-10 (IL-10) and transforming growth factor (TGF) β1 [6], indicating that hucMSCs are a promising approach to controlling SLE disease. This evidence concerns the gene IL10 and systemic lupus erythematosus.